Lysogene (LYSGF) announced that a patient has passed away in the AAVance clinical trial, a global Phase 2/3 gene therapy trial for the treatment of Mucopolysaccharidosis Type IIIA, or MPS IIIA, also known as Sanfilippo syndrome type A.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,